Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...
Neoadjuvant chemotherapy (NAC) is one of the standard-of-care therapies for breast cancer (BC) with axillary lymph node (ALN) metastases. However, the response to this therapy varies depending on the ...
Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...
Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST ...
It is possible to leave most of the lymph nodes in the armpit, even if one or two of them have metastases larger than two millimeters. This is shown in a trial enrolling women from five countries. The ...
It is possible to leave most of the lymph nodes in the armpit, even if one or two of them have metastases larger than two millimeters? This is shown in a trial enrolling women from five countries, led ...
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401 Patients who underwent ...
Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results